Peptide Therapeutics Market

The global Peptide Therapeutics Market is valued at USD 117.26 Billion in 2024 and is projected to reach a value of USD 367 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 10.95% between 2025 and 2035.

Key highlights of Peptide Therapeutics Market

• In 2023, North America exhibited its market prowess, achieving the highest revenue share of over 44.2%
• The Asia Pacific region is poised for remarkable CAGR between 2024 and 2032
• The Metabolic disorder segment accounts for largest market share of 36.5% in 2023
• The branded peptides segment will continue to assert its dominance by type, capturing the largest market share
• In 2023, the Parenteral segment accounted for market share of 80.3%
• In-house manufacturing accounted for a substantial market share of 62.3%
• LPPS (Liquid phase peptide synthesis) segment accounts for market share of 42.2%
• In 2023, Hospital Pharmacies segment accounts for largest market share of 56.2%
• The increasing prevalence of chronic diseases an spurring demand for targeted and personalized treatment are major drivers for the {keyword}} market

Peptide Therapeutics Market: Regional Overview

North America Dominated Sales with a 44.2% share in 2023. There is increased awareness of peptide therapeutic products among consumers. Moreover, theres a developing need for diagnostics in conditions like cancer and other diseases, thats contributing to the market expansion. The excessive incidence of diseases consisting of most cancers, cardiovascular diseases, and diabetes within the vicinity is creating a strong demand for brand new biopharmaceuticals. For instance, the Canadian Cancer Statistics 2021 reported that an estimated 229,200 Canadians were diagnosed with cancer, providing significant opportunities for peptide therapeutics in the market. Similarly, the rising prevalence of chronic diseases like diabetes in Mexico, with an estimated 14 million adults living with the condition in December 2021, is driving the demand for peptides such as amide (GLP-1) for diabetes treatment and contributing to market growth. Government initiatives, such as the transition to biosimilar versions of certain biologic drugs in Nova Scotia, are also playing a crucial role in expanding the market. The adoption of biosimilar drugs by an increasing population is expected to further boost market growth in the region.

U.S. Peptide Therapeutics Market Overview

The U.S. Peptide Therapeutics market, valued at USD 20.4 billion in 2023 to USD 57.26 Billion in 2032 is anticipated to grow at a CAGR of 12.2% from 2024 to 2032. Peptide therapeutics are known for their excessive efficacy and specificity and have become increasingly more vital within the pharmaceutical field, assembly the need for precision medicine. Ongoing research and development efforts aimed at expanding the use of peptides and improving their delivery methods are driving market growth. Additionally, advancements in biotechnology and peptide synthesis, along with the rising prevalence of chronic illnesses, contribute to the expansion of the market. For instance, The American Cancer Societys projections indicate that over 1.9 million new cancer cases are expected to be detected in the United States next year. Cancer ranks as the second main contributor to mortality in the country, following heart disease.

The global Peptide Therapeutics market can be categorized as Type, Application, Route of Administration, Manufacturer Type, Synthesis Technology, Distribution Channel and Region.

Peptide Therapeutics Market: Type Overview

In 2023, the branded peptides segment dominated the market with significant market share. Type segment is divided into Branded peptides, Generic peptides. Branded peptides are typically developed and sold by pharmaceutical companies under specific brand names, setting them apart from generic alternatives. This sectors emphasis on research and development has resulted in the production of peptides with distinct structures and improved therapeutic properties. These exclusive peptides are subject to thorough testing and clinical trials, leading to drugs that exhibit considerable effectiveness and safety. Furthermore, the branding associated with these peptides establishes a unique presence in the market, cultivating trust among medical professionals and patients. With the increasing demand for tailored and individualized treatment choices, the prominence of branded peptides reaffirms their vital role in shaping the field of peptide therapeutics and advancing precision medicine.

Peptide Therapeutics Market: Application Overview

In 2023, the Metabolic disorder Application segment accounted for over 36.5% market share. The Application segment is divided into Metabolic & endocrine disorders, Cancer, Cardiovascular disorders, Gastrointestinal disorders, Central nervous system disorders, Respiratory disorders, Pain management, Renal disorders, Dermatology, Other applications. Metabolic Disorder segment dominates the market due to the increasing prevalence of metabolic disorders worldwide and the recognition of peptides as effective therapeutic agents for managing these conditions. Peptide-based drugs play a essential role in addressing numerous metabolic disorders like diabetes and obesity by way of regulating hormonal pathways and metabolic processes. For instance, Significant health, social, and economic consequences are created by metabolic syndrome (MetS), which affects around 20-30% of the adult population worldwide, as reported in a 2023 article from the National Centre for Biotechnology Information (NCBI). The prominence of the metabolic disorder segment indicates a rising demand for innovative and targeted treatments in this field. With ongoing research and development efforts leading to the introduction of new peptide-based therapies, the peptide therapeutics market for metabolic disorders is anticipated to maintain its strong growth trajectory and significantly contribute to the broader healthcare solutions landscape.

Peptide Therapeutics Market: Route of Administration Overview

In 2023, the parenteral category to witness a substantial share of 80.3% in the global market. Route of Administration segment is divided into Parenteral, Oral, Other routes of administration. The use of injection strategies like subcutaneous, intravenous, and intramuscular routes has made parenteral administration the main choice. This dominance is due to the numerous advantages associated with parenteral administration, consisting of the rapid and unique delivery of the drug, advanced availability of the drug in the body, and direct get entry to to the bloodstream, which leads to quicker therapeutic effects. As both patients and healthcare providers increasingly prioritize treatment options that are efficient and reliable, the fact that the parenteral segment is dominating underscores the crucial role of injectable peptide formulations in meeting these demands and driving advancements in the overall peptide therapeutics market.

Peptide Therapeutics Market: Manufacturing Type Overview

In 2023, In-house manufacturing had a substantial share of 62.3% i.e., a large portion of peptide production is done by pharmaceutical companies themselves. Manufacturing Type segment is further divided into in house and Outsourced. In-house manufacturing dominance highlights the benefits of in-house capabilities, including better cost control, flexibility, and ownership of manufacturing technology. as the demand for peptide therapeutics increases, the dominance of in-house production emphasizes the significance of complete and self-contained manufacturing techniques to meet the converting needs of the market and ensure the quality and efficiency of peptide drug improvement.

Peptide Therapeutics Market: Synthesis Technology Overview

In 2023, in the market for Peptide Therapeutics Liquid phase peptide synthesis (LPPS), had a substantial share of 42.2%. Synthesis Technology segment is divided into Liquid phase peptide synthesis (LPPS), Solid phase peptide synthesis (SPPS), Hybrid technology. LPPS is widely recognized for its efficiency and versatility, making it the top choice for peptide synthesis in the pharmaceutical industry. By allowing the sequential addition of amino acids in solution, this method enables the precise production of complex peptides. The dominance of LPPS reflects its ability to effectively meet market demands for efficient and scalable peptide synthesis. As synthesis technologies advance, the continued dominance of Liquid Phase Peptide Synthesis emphasizes its crucial role in driving innovation and progress within the peptide therapeutics market. This approach offers a reliable and effective means for producing a wide range of peptide-based drugs.

Peptide Therapeutics Market: Distribution Channel Overview

In 2023, the hospital pharmacies category to witness the largest market growth with market share of 56.2%. Distribution Channel segment is divided into Hospital pharmacies, Retail pharmacies, Online pharmacies. Hospital pharmacies are critical access points in the healthcare system, ensuring the availability and proper administration of peptide drugs to patients. The dominance of this segment underscores the strategic value of hospital-based distribution networks, highlighting the integration of peptide therapeutics into the overall healthcare infrastructure. This trend emphasizes the importance of efficient and trustworthy distribution channels in making advanced and targeted therapies easily accessible, ultimately contributing to the ongoing growth and adoption of peptide-based treatments in clinical settings.

Key Trends

• The incorporation of customized medicine approaches is a notable and persistent trend in the Peptide Therapeutics market. Personalized peptide-based therapy is becoming more and more important as genomes and biomarker research continue to progress. By choosing the best peptides based on a patients genetic profile and disease factors, this movement seeks to maximize therapeutic outcomes. A new era of precision medicine in healthcare is being ushered in by pharmaceutical corporations' increased investment in research and development to build individualized peptide medicines.
• The ongoing development of peptide drug pipelines across a range of therapeutic domains is another noteworthy trend. Innovative peptide-based medications are being developed by biotechnology and pharmaceutical companies to diversify their portfolios over a broad spectrum of indications aggressively. Peptides are being investigated as possible possibilities for anything from cancer immunotherapy to neurological diseases. The increasing success rates in clinical trials and our expanding understanding of peptide pharmacology are driving this trend, which suggests that peptide therapies have a bright future in meeting unmet medical needs.
• Peptide therapeutics are gaining broad recognition across medical conditions due to their ease of synthesis, target specificity, and low toxicity. The growing popularity of peptides reflects their promising role as an increasingly accepted class of therapeutic agents with significant potential in diverse medical applications.

Premium Insights

The market for Peptide Therapeutics has been driven by the rising incidence of chronic illnesses and the expanding need for individualized and focused treatments. Pharmaceutical Research and Manufacturers of America (PhRMA) reports that peptide-based medications have demonstrated great promise in the treatment of numerous illnesses, including diabetes, cardiovascular disease, and cancer. Peptide synthesis technology developments, increased R&D spending, and an aging population in need of novel treatment alternatives are some of the causes contributing to this expansion. Further driving market expansion are the move towards biologics and the growing popularity of peptide-based medications because of their high selectivity and low adverse effects. The Peptide Therapeutics market is anticipated to maintain its speed in the next years due to the combined effects of academic research, pharmaceutical alliances, and regulatory assistance.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool : Vantage Point

Market Dynamics

Advancements in Production Processes as Manufacturers and Suppliers Actively Involved in Creating Novel Synthesis Methods Driving Growth

The adoption of more efficient and cost-effective techniques for synthesizing peptides may result in advancements in production processes. This could lead to increased production capabilities, improved scalability, and potentially lower costs. For instance, Companies are Involved in Creative Peptides' introduction of innovative services for peptide drug discovery in March 2022, highlighting the industrys dedication to speeding up therapeutic development using peptides. Peptide synthesis techniques are being advanced thru ongoing research carried out by instructional and research institutes, resulting in the emergence of novel technology for the synthesis of peptide therapeutics. For instance, demonstrating their dedication to tackling pressing concerns like antibiotic resistance, Hokkaido University researchers introduced a groundbreaking approach in February 2023.

Challenges in Adoption Due to Awareness and Complexity among healthcare professionals and end-users

Expanding the global reach and impact of peptide therapeutics is contingent upon addressing various challenges. These challenges consist of insufficient awareness, costly manufacturing equipment, and a scarcity of professionals, particularly in developing and underdeveloped nations among healthcare professionals and end users. Furthermore, the intricate nature of recombinant peptides may generate difficulties in terms of solubility, potentially impeding market growth. It is vital to tackle these challenges in order to ensure the widespread adoption and effectiveness of peptide therapeutics worldwide.

Competitive Landscape

The Peptide Therapeutics market is highly competitive, with major pharmaceutical companies, biotechnology firms, research institutions, and service providers all playing a role. Collaborations between pharmaceutical companies and research organizations are also driving innovation. Start-ups contribute to the diversity of treatment options, while technological solution providers improve peptide synthesis and delivery systems. As the market grows, generic and biosimilar manufacturers are becoming more important in offering affordable alternatives.

The key players in the global Peptide Therapeutics market include - Eli Lilly and Company (U.S.) among others.

Recent Market Developments

• In March 2023, Ono Pharmaceuticals and PeptiDream have formed a partnership to collaborate on the discovery and development of Macrocyclic Constrained Peptide Therapeutics for drug purposes.
• In September 2023, By acquiring Pepceuticals Limited, a synthetic peptide manufacturer based in Britain, Biosynth aimed to bolster its peptide division and enhance its overall capabilities in the industry.
• In September 2023, The FDA has recently released draft guidance concerning clinical pharmacology and labeling for peptide drug products. In this guidance, the FDA discourages the use of radiolabeled mass balance studies and mandates the assessment of immunogenicity risk for all products. Additionally, the FDA recognizes the possibility of hepatic impairment affecting the pharmacokinetics of specific peptide drug products.
• In June 2023, Asep Medical received a US$ 200,000 grant from the NanoMedicines Innovation Network to develop a nanoparticle-formulated peptide solution for treating chronic sinus infections caused by biofilms. The grant, funded by Canadas Networks of Centres of Excellence, will aid pre-clinical studies and clinical trials.
• In May 2023, In an effort to speed up peptide drug discovery research, Fujitsu introduced the "Biodrug Design Accelerator" platform. This platform aligns with the companys "Healthy Living" vision and helps scientists in their designing, creating, testing, and analyzing process. It allows for well-informed design of peptide drug candidates and effective communication. Currently compatible with HELM, the platform is set to further extend its support to nucleic acid and antibody drugs.
• In December 2022, Enterome used its bacterial-mimicking drug discovery platform to create one of the first-in-class immunomodulatory medications. To treat patients with initial progression or recurrence of glioblastoma, Enterome published the safety, immunogenicity, and effectiveness findings of their Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (ROSALIE trial).
• In September 2022, Albumedix Ltd. was acquired by the life science business Sartorius through its French-listed unit Sartorius StedimBiotech. One of the major participants in the field of recombinant albumin-based solutions is Albumedix.